Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor
- PMID: 8313362
Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor
Abstract
Single-chain immunotoxins anti-Tac(Fv)-PE40 and anti-Tac(Fv)-PE40KDEL, composed of variable domains of the anti-Tac monoclonal antibody and truncated forms of Pseudomonas exotoxin, have shown potent cytotoxic activity against malignant peripheral blood mononuclear cells (PBMCs) from adult T-cell leukemia (ATL) patients originating from the Caribbean. However, several clinically important issues have not previously been addressed. These include the potential of soluble interleukin 2 receptor in ATL patients to block immunotoxin effectiveness, the relative sensitivity of malignant lymph node cells (LNCs) versus PBMCs, the effect of an immunotoxin with a prolonged half-life, and finally whether ATL cells from patients in Japan have toxin sensitivity equal to those of the Caribbean patients. To resolve these questions, we studied 32 malignant PBMC and LNC samples from 30 ATL patients from Japan. PBMCs from 27 of 27 patients were very sensitive with 50% inhibition of protein synthesis achieved with 0.02-0.85 ng/ml (0.3-13 pM) of anti-Tac(Fv)-PE40KDEL or anti-Tac(Fv)-PE40. LNCs had sensitivity very similar to that of PBMCs in the five patients tested. The fully recombinant immunotoxin, anti-Tac(Fab)-PE40, which has 8-10 times the t1/2 alpha and beta compared to the Fv-immunotoxins, was also very cytotoxic toward cells from 27 of 27 patients tested with 50% inhibition of protein synthesis of 0.08-25 ng/ml. It was found that purified soluble interleukin 2 receptor added to the cytotoxicity assay decreased the cytotoxic activity of anti-Tac(Fv)-PE40KDEL or anti-Tac(Fab)-PE40, but that 1 x 10(4) units/ml or less had minimal competitive effects. It was found that ATL patients who have responded even incompletely to conventional chemotherapy have soluble interleukin 2 receptor levels lower than this at posttreatment. We conclude that recombinant immunotoxins containing anti-Tac(Fv) are effective against Japanese ATL PBMCs or LNCs and might be most effective if used in vivo after conventional chemotherapy. If it is found in humans that the effectiveness of single-chain recombinant toxins is limited by short half-life, anti-Tac(Fab)-PE40 should be considered as an alternative agent.
Similar articles
-
The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.Proc Natl Acad Sci U S A. 1990 Nov;87(21):8291-5. doi: 10.1073/pnas.87.21.8291. Proc Natl Acad Sci U S A. 1990. PMID: 2236041 Free PMC article.
-
Recombinant single-chain immunotoxins against T and B cell leukemias.Leuk Lymphoma. 1994 Mar;13(1-2):1-10. Leuk Lymphoma. 1994. PMID: 8025511 Review.
-
Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.Blood. 1992 Nov 1;80(9):2344-52. Blood. 1992. PMID: 1421405
-
Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.Leukemia. 1993 Apr;7(4):553-62. Leukemia. 1993. PMID: 8464234
-
Targeting Pseudomonas exotoxin to hematologic malignancies.Semin Cancer Biol. 1995 Oct;6(5):297-306. doi: 10.1006/scbi.1995.0038. Semin Cancer Biol. 1995. PMID: 8562907 Review.
Cited by
-
Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.Clin Cancer Res. 2016 Jan 15;22(2):310-8. doi: 10.1158/1078-0432.CCR-15-1412. Epub 2015 Sep 8. Clin Cancer Res. 2016. PMID: 26350263 Free PMC article. Clinical Trial.
-
Clinical targeting recombinant immunotoxins for cancer therapy.Onco Targets Ther. 2017 Jul 20;10:3645-3665. doi: 10.2147/OTT.S134584. eCollection 2017. Onco Targets Ther. 2017. PMID: 28790855 Free PMC article. Review.
-
Immunoconjugates in the management of hairy cell leukemia.Best Pract Res Clin Haematol. 2015 Dec;28(4):236-45. doi: 10.1016/j.beha.2015.09.003. Epub 2015 Oct 9. Best Pract Res Clin Haematol. 2015. PMID: 26614902 Free PMC article. Review.